{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"DOR: The number of days between the first tumor response assessment of objective response (complete response and partial response) to the time of the first tumor response assessment of progressive disease (PD) or death if due to disease progression (date of first PD assessment or death due to disease progression-date of first objective response assessment +1).","groups":[{"description":"Brentuximab vedotin will be given intravenously with a dose of 1.8 mg/kg every 21 days, over 30 minutes for 16 cycles in the clinic.","id":"OG000","title":"Brentuximab Vedotin Treatment"}],"populationDescription":"Participants with Complete Response or Partial Response.","reportingStatus":"POSTED","timeFrame":"Up to 24 months post treatment","title":"Duration of Response (DOR)","type":"SECONDARY"}